Theravance Biopharma (FRA:0TB) Total Stockholders Equity : €188.48 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Total Stockholders Equity?

Theravance Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €188.48 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Theravance Biopharma's Book Value per Share for the quarter that ended in Mar. 2024 was €3.88. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Theravance Biopharma's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.23.

Theravance Biopharma Total Stockholders Equity Historical Data

The historical data trend for Theravance Biopharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Total Stockholders Equity Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

-201.46

-249.68

-299.64

417.06

195.32

Theravance Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															346.10	258.59	230.62	195.32	188.48

Theravance Biopharma (FRA:0TB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Theravance Biopharma's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(188.479	-	0)	/	48.566
	=	3.88

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Theravance Biopharma's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.738	+	40.333)	/	188.479
	=	0.23

Theravance Biopharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (FRA:0TB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

TBPH:USA

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines